Marion Gasperment

SpineVision SA develops and markets implants for the treatment of spinal disorders. It also designs instrumentation for the spinal treatments. Its products include Flex 2, Lumis, Plus/X-Plus, ULIS, Unithread, Spacevisions, and C3. The firm also offers solutions for spinal pathologies, such as lumbar degenerative disc diseases, deformities, cervical disorders, trauma, and tumors. The company was founded by Gérard Vanacker on July 16, 1999 and is headquartered in Antony, France.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Touchstone Innovations Businesses LLP commercializes academic research and technology businesses. The company was founded on December 19, 2007 and is headquartered in London, the United Kingdom.

France Invest is a French association of investors for growth that supports private equity as a lever for business creators and managers to achieve growth. The private company is based in Paris, France and was founded by Maurice Tchenio. The association is at the heart of the economy and aims to share the value created by supporting companies in their innovation and energy transition efforts.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

MD Start SA develops medical device technology. It has collaboration between venture capital, institutional investors and industry to the development of innovative medtech ideas in Europe. The company was founded by Tim Lenihanin 2010 and is headquartered in Paris, France.

Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom.

ReCor Medical, Inc. develops novel therapeutic ultrasound catheter technologies The firm develops a therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The company was founded by Mano Iyer and Jacques Seguin in July 2009 and is headquartered in Palo Alto, CA.

Reflexion Medical, Inc. develops medical devices. Its products include marketwired resonate and influencers, news distribution, IR and PR hosted newsroom and media database. The company was founded by Akshay Nanduri and Samuel Mazin in 2009 and is headquartered in Hayward, CA.

HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France.

Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal.

Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.

CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

Biovelocita Srl (Biovelocita) is a venture capital firm founded in 2015 by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. The firm is headquartered in Milan, Italy.

Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany.

LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France.

SafeHeal SAS develops anastomosis protection devices for improved patient recovery and reduced healthcare costs. The company is headquartered in Paris, France.

May Health SAS engages in the development of device for the treatment of polycystic ovary syndrome infertility. The company was founded in September 2017 and is headquartered in Paris, France.

GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020.

Nephris Srl provides pre-clinical and research services for kidney diseases. The company is based in Milan, Italy. The Italian company was founded in 2021 by Paolo Fiorina, Francesca D'Addio. The CEO is Maria Gabriella Camboni.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.